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Speciﬁc microRNAs have emerged as key players in disease biology by playing crucial
role in disease development and progression. This review draws attention to one such
microRNA, miR-191 that has been recently reported to be abnormally expressed in
several cancers (>20) and various other diseases like diabetes-type 2, Crohn’s, pulmonary
hypertension, and Alzheimer’s. It regulates important cellular processes such as cell
proliferation, differentiation, apoptosis, and migration by targeting important transcription
factors, chromatin remodelers, and cell cycle associated genes. Several studies have
demonstrated it to be an excellent biomarker for cancer diagnosis and prognosis leading
to two patents already in its kitty. In this ﬁrst review we summarize the current knowledge
of the regulation, functions and targets of miR-191 and discuss its potential as a promising
disease biomarker and therapeutic target.
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INTRODUCTION
MicroRNAs are a class of small non-coding RNAs that function
as post-transcriptional gene regulators (Bartel and Chen, 2004).
Volinia et al. (2006) for the ﬁrst time suggested the association
of solid tumors with dysregulation of speciﬁc microRNAs. Since
thenmiRNA-cancer link has extendedbeyond reports of abnormal
miRNA levels in various cancers to miRNAs acting themselves as
oncomiRs or tumor-suppressors. However, functional signiﬁcance
of majority of dysregulated miRNAs has not been elucidated. We
have focused here on one such highly conserved miRNA, miR-
191 that was found to be abnormally expressed in more than
twenty different cancers and shown to be a major player in some
of these. Further, altered expression of miR-191 has also been
associated with various other diseases such as type 2 diabetes,
neurodegenerative diseases, and more recently with innate immu-
nity (Saba et al., 2008; Xu et al., 2009; Zampetaki et al., 2010). This
review is timely to highlight the crucial role miR-191 plays in a
multitude of diseases including cancer and also in normal devel-
opment and differentiation processes. We start off with a small
introduction to miR-191/425 cluster and its regulation followed
by summarizing studies on functional dissection of miR-191 in
various cancers. Overall, current understanding of miR-191 biol-
ogy suggests it to be a promising novel target for cancer prognosis
and therapy.
miR-191/425 CLUSTER
miR-191 is expressed as part of the miR-191/425 cluster which
is highly conserved in several metazoan species (miR-425 in 26
species, miR-191 in 30 species) suggesting it to be an important
player in higher eukaryotes (Kiezun et al., 2012). First discov-
ered in mouse, its expression was later conﬁrmed in humans
in a leukemia cell line (HL-60) and subsequently in 20 differ-
ent human tissues (Lagos-Quintana et al., 2003; Kasashima et al.,
2004). This cluster is located in the ﬁrst intron of DALRD3
gene on human chromosome 3 (3p21.31) and codes for four
mature miRNAs – miR-191-5p, miR-191-3p, miR-425-5p, and
miR-425-3p. It forms a sense antisense transcript pair with
DALRD3, NDUFA3, and WDR6 mRNAs; however, the functional
impact of this association has not been experimentally evaluated
(Grifﬁths-Jones et al., 2006). miR-191 tends to be coexpressed
with the DALRD3 and NDUFAF3 transcripts. miR-191 resides
381 nucleotides upstream of miR-425 and notably shows much
higher expression or cloning frequency as compared to miR-425
in all the tissues studied so far (Altuvia et al., 2005; Di Leva et al.,
2013). This is in compliance with recent reports showing that
huge variations in expression levels of miRNA members may exist
within the same cluster (Vaz et al., 2010). Indeed, Croce and Kul-
shreshthas group have shown that both miR-191 and miR-425
promote cell proliferation in breast cancer exhibiting overlap-
ping functions, but a previous study shows that miR-191 and not
miR-425 promotes erythroid enucleation (Zhang et al., 2011; Di
Leva et al., 2013; Nagpal et al., 2013). Therefore, with very lim-
ited data, we assume that miR-191 and miR-425 may exhibit
speciﬁc or overlapping functions depending on the tissue and
conditions.
miR-191 IN DEVELOPMENT AND DIFFERENTIATION
The ﬁrst report that miR-191 is developmentally regulated came
from the observation that signiﬁcantly high levels of miR-191were
present in (postmortem) human prefrontal cortex specimens of
individuals older than 41 years than those under 15 years. It
was suggested that miR-191 mediated downregulation of brain-
derived neurotrophic factor (BDNF; predicted miR-191 target)
may contribute to the cortical development (Mellios et al., 2008).
miR-191 is also one of the major miRNA expressed in rat neurons
and its expression increases ∼2–5 fold with time in rat cortical
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cultures suggestive of its role in neuronal development (Kim et al.,
2004).
Developmental association of miR-191 was further extended
to senescence since its overexpression was shown to promote
replicative senescence and inhibit proliferation in primary human
keratinocytes (Lena et al., 2012). Role of miR-191 in regulation of
circadian rhythm was also suggested as it was shown to exhibit a
circadian pattern of expression in mouse liver and showed inverse
correlation to Bma-1 (circadian transcription factor) levels (Na
et al., 2009).
The connection of miR-191 and differentiation was also
explored recently. miR-191 was found to be signiﬁcantly down-
regulated during terminal erythroid differentiation (CFU-E to
the Ter119+ stage) while its overexpression inhibited erythroid
enucleation and chromatin condensation suggesting that miR-
191 plays a crucial role in erythropoiesis (Zhang et al., 2011).
Levels of miR-191 were also found to be differentially expressed
in monocytes vs. monocytes derived dendritic cells (Cekaite
et al., 2010). Induced miR-191 levels were observed in osteoblast
like cells following treatment with Bio-Oss (an organic bovine
bone). As Bio-Oss plays an important role in bone regenera-
tion thus miR-191 may be an important mediator for the same
(Palmieri et al., 2010). Therefore, all these ﬁndings suggest that
miR-191 plays an important role in cellular differentiation and
development.
miR-191 AND CANCER CONNECTION
miR-191 and cancer abnormalities have been reported in more
than twenty different malignancies making the miR-191 a ubiqui-
tously notorious miRNA like miR-21 or miR-155. Overexpression
of miR-191 in 16 different cancer types [breast (female), colon,
lung, liver, prostate, pancreas, stomach, ovarian cancer, pitu-
itary adenoma, esophageal squamous carcinoma, oral squamous
carcinoma, osteosarcoma, B-ALL, bladder, anaplastic large cell
lymphoma, and acutemyeloid leukemia (AML)] classiﬁes it largely
as an oncogenicmiRNA.However, in six other cancer types (severe
medulloblastomas, retinoblastoma, thyroid follicular tumor, male
breast cancer, CALL, and melanoma) its levels are known to be
downregulated (Volinia et al., 2006; Xi et al., 2006; Garzon et al.,
2008; Fassan et al., 2009; Ferretti et al., 2009; Fulci et al., 2009; Hui
et al., 2009; Kent et al., 2009; Caramuta et al., 2010; Elyakim et al.,
2010; Patnaik et al., 2010; Shen et al., 2010; Colamaio et al., 2011;
Duan et al., 2011; He et al., 2011; Leite et al., 2011, 2013; Li et al.,
2011; Shi et al., 2011; Xu et al., 2011; Inoue et al., 2012; McEvoy
et al., 2012; Poliseno et al., 2012; Di Leva et al., 2013; Gombos
et al., 2013; Liu et al., 2013a; Nagpal et al., 2013; Zhou et al., 2013;
Scheffer et al., 2014). The nature of miR-191 deregulation, its func-
tions and targets reported so far in various cancers are shown in
Table 1.
miR-191 AS A BIOMARKER FOR CANCER DIAGNOSIS AND PROGNOSIS
Since miR-191 is one of the highly expressed and stable miRNA in
human serum or saliva, it shows potential of being used as non-
invasive biomarker in human subjects (Patel et al., 2011). A new
method for the disease characterization based upon blood circu-
lating miRNAs was proposed recently. It involved both miR-191
and miR-425 as part of a unique combination of 12 miRNAs that
could serve as potential biomarkers to distinguish disease/cancer
from healthy controls in 10 out of 13 diseases (p = 0.046; Taguchi
and Murakami, 2013). Zhang et al. (2012) recently ﬁled a patent
involving a group of 7 miRNAs including miR-191 that serve as
markers for prediction, diagnosis, and progression of pancreatic
cancer. Similarly, miR-191 (along with miR-182 and miR-199a)
based methods for diagnosis and prognosis of AML have been
recently patented (Croce, 2013). Higher expression of miR-191
was found to be signiﬁcantly associated with poor overall survival
(OS) and event free survival in adult AML patients (Garzon et al.,
2008). Also, in colorectal cancer patients, higher miR-191 expres-
sion has been shown to be associated with clinical stage,metastasis
and tumor invasion (Xi et al., 2006). In contrast, reduced miR-191
levels have been reported to be associated with bad prognosis or
short OS or disease relapse in melanoma, pediatric AML or male
smoker squamous cell carcinoma (SCC) patients (Mueller et al.,
2009; Zhang et al., 2009; Caramuta et al., 2010; Landi et al., 2010;
Xu et al., 2011).
Apart from miR-191 alone as a prognostic marker, the miR-
146b/miR-191 ratio has also been reported as a negative prognostic
indicator in lung SCC patients (0.29+0.25; Ernest et al., 2012).
Likewise, Mar-Aguilar et al. (2013a) have shown that combined
expression proﬁle of two miRNAs (miR-125b/miR-191 and miR-
21/miR-191) is more speciﬁc in discriminating between breast
cancer and non-tumor tissue (Mar-Aguilar et al., 2013a). Inter-
estingly, presence of genetic variants in miR-191 precursor has
been linked to genetic predisposition to familial ovarian cancer
and could therefore serve as a diagnostic marker (Duan et al.,
2011). Additionally, epigenetic regulation (hypomethylation) of
miR-191 locus has been associated with poor prognosis in hepato-
cellular carcinoma (HCC; He et al., 2011). Hence, quantiﬁcation
of miR-191/its precursor variants/methylation patterns of its pro-
moter using tissue/blood samples may emerge as a novel method
for cancer diagnosis and prognosis.
miR-191 AS A REGULATOR OF VARIOUS HALLMARKS OF CANCER
While there are ample reports on abnormal miR-191 levels in var-
ious cancers, the knowledge about its functional impact is quite
limited. Studies in breast, colon, gastric, and hepatic cancer cell
lines suggest miR-191 to be an oncomiR (Xi et al., 2006; Elyakim
et al., 2010; Shi et al., 2011; Di Leva et al., 2013; Nagpal et al., 2013).
miR-191 was shown to be involved in regulation of cell prolifer-
ation, apoptosis, and epithelial mesenchymal transition in HCC
(Elyakim et al., 2010; He et al., 2011). In colon cancer, anti-miR-
191was shown to attenuate the invasiveness, suppress proliferation
and induce apoptosis and in gastric cancer, miR-191 overexpres-
sion was shown to enhance cell proliferation and reduce apoptosis
(Shi et al., 2011; Qin et al., 2014). However, functional analysis of
miR-191 levels in pancreatic ductal carcinoma cells showed that
although it is responsible for maintaining the transformed stage
but cell proliferation is not affected (Kent et al., 2009). Recently,
Nagpal et al. (2013) showed that miR-191 is responsible for pro-
motion of various hallmarks of cancer (proliferation, metastasis,
stress resistance) in ER+ breast cancer (MCF7) cells, while Di Leva
et al. (2013) demonstrated that miR-191/425 cluster is responsible
for reduced proliferation, tumorigenesis, and metastasis in aggres-
sive ER- breast cancer cells (MDA-MB-231; Di Leva et al., 2013;
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Nagpal et al., 2013). This dual effect of miR-191 could be due to
the fact that miR-191 is an ER regulated miRNA that functions as a
critical mediator of estrogen mediated cell proliferation. miR-191
has been shown to regulate cell cycle progression in breast cancer
by promoting G1/S and G2/M transitions as the cells overexpress-
ing miR-191 entered S-phase much faster with drastic reduction
in G0/G1 phase.
In contrast, miR-191 has been projected as a tumor-suppressor
microRNA that leads to reduced growth and migration in thyroid
follicular carcinoma (Colamaio et al., 2011). Notably, thoughmiR-
191 was shown to be differentially expressed (signiﬁcantly upreg-
ulated in both squamous and non-squamous NSCLC, p < 1e-07)
in lung cancer, it was shown to not alter cell cycle, proliferation
or chemosensitivity of lung cancer cell lines (Volinia et al., 2006;
Yanaihara et al., 2006; Patnaik et al., 2010).
miR-191 AS A THERAPEUTIC TARGET IN CANCER
Till date only two groups have performed mouse xenograft assays
to test miR-191 activity in vivo evaluating its therapeutic poten-
tial and the results are certainly encouraging. Elyakim et al. (2010)
generated an orthotopic human liver tumor xenografts in nude
mice and administered 2-O-metoxyethyl (MOE) anti-miR-191
through repeated intraperitoneal injections. A statistically signif-
icant reduction in tumor mass was observed without toxicity by
the end of 40 days (Elyakim et al., 2010). Similarly, a subcutaneous
transplantation of the anti-miR-191 transfected ER-alpha positive
MCF7 or ZR-75-1 breast cancer cells in nude mice resulted in a
50% reduction in tumormass. The effect of miR-191 onmetastasis
was also studied in aggressive breast cancer. Injection of miR-191
overexpressing ER negative breast cancer cells (MDA-MB-231)
in NOD-SCID mice led to a signiﬁcant reduction in a number
of micrometastasis to lungs of mice as compared to the con-
trol tumor cells (Di Leva et al., 2013). Thus, regulated expression
of miR-191 may serve as potential therapeutic treatment of the
disease.
REGULATION OF miR-191 EXPRESSION IN CANCER
Despite well documented miR-191 and cancer links, very little is
known about the factors that lead to its deregulation in various
tumor cells. In breast cancer, two independent groups demon-
strated that estrogen and tumor microenvironment play a major
role in regulation of miR-191 (Di Leva et al., 2013; Nagpal et al.,
2013). The promoter of miR-191 bears estrogen response elements
which show dynamic binding of ER-alpha and ER-beta transcrip-
tion factors in response to estrogen treatment (Nagpal et al., 2013).
The levels of both miR-191 and miR-425 have been reported to be
estrogen inducible (Di Leva et al., 2013; Nagpal et al., 2013). Tumor
microenvironment (hypoxia and nutrient deprivation) has also
been reported to strongly induce miR-191 in breast cancer (Nag-
pal et al., 2013). A report by Xi et al. (2006) suggests that the loss of
p53 may be the reason behind higher expression (median 1.4-fold,
p 0.0264) of miR-191 in colorectal tumor. Another study shows
that the gain in expression of MDM4, a miR-191 target gene, in
retinoblastoma leads to inactivation of p53 activity (McEvoy et al.,
2012). Interestingly, the hypomethylation of CpG islands in miR-
191 promoter has been linked to higher expression of miR-191
in HCC (He et al., 2011). While in melanoma, both, the genomic
loss of the miR-191 locus and downregulation of miR-191 by a
transcription factor, SNAIL have been shown as the reasons for
low miR-191 levels (Mueller et al., 2009; Poliseno et al., 2012).
To conclude, transcription factors, tumor microenvironment and
epigenetic mechanisms play major role in regulation of miR-191
in various cancers.
Several recent reports suggest that miR-191 levels are also
responsive to chemical drugs and radiation treatments. Chaudhry
et al. (2013) have shown miR-191 induction in response to X-ray
treatment in human lymphoblast cells (TK6 cell line). How-
ever, miR-191 was shown to be rather downregulated in two
colon cancer cell lines HCT116 and HCT-8 when treated with
chemotherapeutic drugs (5-Fluorouracil and Oxaliplatin; Zhou
et al., 2010). Thus, the effects on miR-191 levels may vary depend-
ing on the stress or tissue/cell type. Work in our lab shows that
miR-191 overexpressing breast cancer cells show increased sur-
vival in response to chemotherapeutic drug or hypoxia treatment
(Nagpal et al., 2013). Altogether these reports suggest prospects of
miR-191being a target for studying chemotherapeutic interference
(Zhou et al., 2010).
Interestingly, carcinogens too have been reported to mediate
miR-191 regulation. Davidson et al. (2009) showed that AOM
(carcinogen) treated rats show downregulation of miR-191. Con-
versely, feeding rats with ﬁsh oil rich in polyunsaturated fatty acids
(n = 3 PUFA; a chemoprotective agent) prevented AOM mediated
downregulationof miR-191 and tumor formation (Davidson et al.,
2009). Environmental carcinogens also play a major role in regula-
tion of miR-191, for example, cigarette smoke andTCDD(a dioxin
family carcinogen) was shown to regulate miR-191 levels in rat
lungs and hepatic cancer, respectively (Izzotti et al., 2009; Elyakim
et al., 2010). Thus, these data provide evidence for hormonal,
environmental and dietary regulation of miR-191.
miR-191 IN DISEASES OTHER THAN CANCER
Association of miR-191 is not only limited to various cancers but
its irregular expression and functional abnormalities have been
reported in a variety of other diseases as well (Table 1). The func-
tional impact of miR-191 is still unknown in these diseases but
it does show potential as a diagnostic or prognostic marker for
some of them. Recently Lin et al. (2013) reported that miR-191
may be a diagnostic biomarker candidate that could help to dis-
tinguish between the Crohn’s disease (CD) and ulcerative colitis
(UC; Lin et al., 2013). Further, as the two disease types differ in
their associated T- and B- cells, miR-191 may be involved in reg-
ulation of innate and adaptive immunity as well (Paraskevi et al.,
2012). Similarly, miR-191 was shown to be a potential biomarker
for early detection and severity of pulmonary hypertension (Wei
et al., 2013). Remarkably, miR-191-5p was shown to be one of the
best biomarker candidates to predict the Alzheimer’s disease with
>95% accuracy (Kumar et al., 2013). miR-191 was also found to
be signiﬁcantly induced (3.79-fold, p < 0.0001) in nephrotic syn-
drome (NS) children making it a potential diagnostic marker for
pediatric NS. Interestingly, NS patients under remission have sig-
niﬁcantly reduced level of miR-191 suggestive of its association
with disease progression and therapy (Luo et al., 2013). Over-
all, miR-191 seems to be closely associated with the pathogenesis
of diverse diseases and may also be involved in innate immune
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responses. A compiled list of diseases having an association with
miR-191 is given in Table 1.
miR-191 TARGETS
A number of miR-191 targets have been validated and charac-
terized functionally. Its targets range from chromatin remodel-
ers to transcription factors to cell cycle regulators. A detailed
analysis of the validated potential targets of miR-191 is given
below:
TRANSCRIPTION FACTORS AND CHROMATIN REGULATORS
SATB1 (special AT-rich sequence-binding protein-1)
Special AT-rich sequence-binding protein-1 is a global chromatin
remodeler and transcription factor that is known to be over-
expressed in several cancers and also associated with aggressive
phenotype in colorectal and breast cancer (Cai et al., 2006; Han
et al., 2008; Meng et al., 2012). miR-191 mediated downregulation
of SATB1 has been linked to gain/loss of epithelial/mesenchymal
markers in aggressive breast cancer and enhanced cell prolifera-
tion and migration in hormone dependent breast cancer (Di Leva
et al., 2013; Nagpal et al., 2013). The miR-191/SATB1 functional
linkhas beenproposed to behelpful for prognosis and therapeutics
of breast cancer (Nagpal et al., 2013). Additionally, suppression of
SATB1 was demonstrated to be linked to cell senescence, as its sup-
pression by miR-191 led to enhanced senescence in keratinocytes
(Lena et al., 2012).
RIOK3 (RIO kinase 3) and MXI1 (max-interacting protein 1)
RIO kinase 3 and max-interacting protein 1 are reported to be
negatively regulated by miR-191 and play essential role in chro-
matin condensation and enucleation during mouse erythroid
differentiation (Zhang et al., 2011).
EGR1 (early growth response protein 1)
Early growth response protein 1 is a zinc ﬁnger transcription factor
mainly involved in cell growth, development and stem cell home-
ostasis (Yan et al., 2000). It was demonstrated to be an estrogen
responsive miR-191 target, having regulatory role in cell prolifer-
ation in ER-alpha positive breast cancer cells. Additionally, it was
reported to be downregulated by miR-191 in scrapie infection, a
prion disease (Saba et al., 2008; Di Leva et al., 2013).
SOX4 SRY (sex determining region Y)-box 4
Sex determining region Y-box 4 is a transcriptional factor found
to be upregulated in various cancers (Rhodes et al., 2004). It is
involved in regulation of development, differentiation, prolif-
eration, apoptosis, and more recently epithelial-mesenchymal-
transition (Pan et al., 2009). It was shown to be a novel target
of miR-191 in HCC (Elyakim et al., 2010). Thus, downregulation
of SOX4 bymiR-191may affect chromatin architecture and crucial
cellular processes.
MDM4 (Mdm4 p53 binding protein homolog)
Mdm4 p53 binding protein homolog is a negative regulator of
transcription factor, p53 and is found to be overexpressed in
17% of all cancers (Liu et al., 2012). miR-191 is reported to
regulate cancer progression and chemosensitivity in ovarian can-
cer by modulating the level of MDM4 through binding with an
illegitimate site (rs4245739) within the 3′ UTR (Wynendaele et al.,
2010). Recently, the same SNP (rs4245739) was investigated and
found to be a risk factor for esophageal SCC and breast can-
cer (Zhou et al., 2013). The MDM4 rs4245739 SNP alone or
in combination with the p53 variant Arg72Pro has been shown
to be responsible for attenuating breast cancer risk in Chinese
population (Liu et al., 2013b).
CELL CYCLE REGULATORS
CDK6 (cyclin-dependent kinase 6)
Cyclin-dependent kinase 6 is a protein kinase mainly associ-
ated with cell cycle progression and differentiation (Robker and
Richards, 1998; Depamphilis et al., 2012). It has been reported as
a bona ﬁde target of miR-191 in aggressive and hormone recep-
tor positive breast cancer and thyroid and follicular carcinoma
(Colamaio et al., 2011; Di Leva et al., 2013; Nagpal et al., 2013).
Additionally, miR-191 mediated downregulation of CDK6 has
been reported to trigger senescence in keratinocytes (Lena et al.,
2012).
CCND2 (cyclin D2)
Cyclin D2 is a cell cycle regulatory protein involved in estrogen
mediated cell proliferation (Robker and Richards, 1998). It was
recently established as a target of miR-191 and its downregulation
led to suppression of PI3/AKT pathway thereby leading to reduced
cell proliferation in aggressive breast cancer (Di Leva et al., 2013).
OTHERS
NDST1 (N-deacetylase/N-sulfotransferase1)
N-deacetylase/N-sulfotransferase1 is a key enzyme involved in the
biosynthesis of heparan sulfate chains and is responsible for main-
tenance of physiological functions (Sheng et al., 2011). It regulates
binding of FGF to mammary epithelial cells leading to branch-
ing morphogenesis (Crawford et al., 2010). It was shown to be
negatively regulated by miR-191 and its downregulation has sup-
pressive effect on cell proliferation in gastric carcinoma (Shi et al.,
2011).
BDNF (brain-derived neurotrophic factor)
Brain-derived neurotrophic factor is a neurotrophin essential
for differentiation, survival, and synaptic plasticity of CNS
(Numakawa et al., 2011). Recently our group has shown it to be a
target of miR-191 in ERpositive breast cancer (Nagpal et al., 2013).
TIMP3 (tissue inhibitor of metalloprotease 3)
Tissue inhibitor of metalloprotease 3 is a proapoptotic protein
whose expression is negatively correlated with cell growth and
invasiveness (Kashiwagi et al., 2001). It is a directmiR-191 target in
colorectal carcinoma and its targeted downregulation is associated
with enhanced invasiveness of the disease (Qin et al., 2014).
An overview of miR-191 regulatory components along with
its functional impact on direct and indirect targets is given in
Figure 1.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Our review brings to limelight an important player in cancer biol-
ogy that has been shown to have profound effects on various
hallmarks of cancer. Due to its ubiquitous role in various biological
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FIGURE 1 | A Schematic view of regulation of miR-191 and its
targets: a molecular model is presented whereby hormones
(estrogen), tumor microenvironment (hypoxia and serum stress)
and DNA damage signals (chemodrugs, radiation and carcinogens)
regulate miR-191 levels in the cancer cells. In response, miR-191
controls the expression of a number of genes involved in a variety
of cellular processes (ranging from cell proliferation to apoptosis to
cell migration) to modulate the development of cancer. Overall,
miR-191 integrates multiple pathogenic signals to regulate cancer
phenotype.
processes, the interest in miRNA-191 is likely to dramatically
increase in coming years, especially in cancer. Though various
studies document miR-191 association with cancer progression,
but its link to cancer initiation has not yet been elucidated. How-
ever, since carcinogens have been shown to regulate the levels
of miR-191, it may be involved in tumor initiation process as
well.
Considering the widespread association of miR-191 to several
cancer types and recent studies documenting that its inhibi-
tion leads to reversal of cancer phenotype, it is tempting to
speculate that miR-191 may qualify as a candidate for “onco-
gene addition.” However, the validation of this concept warrants
careful and extensive experimentation using genetically engi-
neered mouse models of miR-191. These models may also throw
light on the role of miR-191 in various stages of tumor devel-
opment. Nevertheless, based on miR-191-lung cancer studies,
miR-191 may not necessarily functionally contribute to aggres-
sion of all cancer/diseaseswhere its levels are abnormally expressed
(Patnaik et al., 2010).
Interestingly, several types of abnormalities have been linked
to miR-191 in cancer. These include but may not be limited to
aberrant mature miR-191 levels, hypomethylated miR-191 pro-
moter, mutations in miR-191 target site or loss of genomic locus
(Caramuta et al., 2010; He et al., 2011). However, there are very
few reports depicting the basis behind its altered expression in
disease states compared to that of normal. Till date transcrip-
tion factors, tumor microenvironment and epigenetic regulation
have been identiﬁed as the major players responsible for aber-
rant expression of miR-191 in various disease states (He et al.,
2011; Di Leva et al., 2013; Nagpal et al., 2013). A strong estrogen
and hypoxic regulation of miR-191 have been shown to regulate
key pathways in breast cancer (Di Leva et al., 2013; Nagpal et al.,
2013). In light of recent reports of interdependence of estrogen
and hypoxia pathways, it would be interesting to know if miR-
191 functions to connect the two pathways. Further, considering
miR-191 to be stress inducible and its reported effects on apopto-
sis, it would be interesting to see if p53 is directly involved in its
regulation.
Owing to highly consistent and stable expression of miR-191
and the ability to detect it in human saliva or serum, miR-191
emerges as a strong candidate for non-invasive disease diagnostics
(Patel et al., 2011). A strong association between miR-191 levels
and disease prognosis/survival laid basis for two recent patents
featuring miR-191 based diagnosis and prognosis in AML and
pancreatic cancer (Zhang et al., 2012; Croce, 2013). It is likely
that miR-191 may emerge as an independent or a co-prognostic
marker in other cancers as well. Use of disease speciﬁc mouse
models, conditional transgenic as well as knockouts are required
to elucidate its functional role in vivo and verify its therapeu-
tic potential, both of which remain largely unexplored till now.
More novel approaches such as combination of Argonaute protein
immunoprecipitation, deep sequencing, or proteomic proﬁling
approaches are required to identify its potential bona ﬁde targets
responsible for its functional impact. The fact that miR-191 may
directly enhance target transcript levels is striking and needs fur-
ther elucidation of the mechanism. In particular a combination of
phenotypic, transcriptomic, proteomic, andmetabolomic changes
on manipulation of miR-191 levels in cell line or mouse models
will provide a complete understanding of miR-191 functions. To
conclude, achieving ways to regulate the level of this particular
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microRNA in patients (in a safe and consistent manner) might
help to ﬁght the underlying disease.
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